循环促炎生物标志物的动力学,用于预后评估患有晚期HCC的患者 - - 来自SORAMIC试验的子研究
Kerstin Schütte1,2,3, Juozas Kupčinskas4, Egidijus Morkunas4
1Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
在治疗过程中,介质素6 (IL-6) 水平的变化预测了晚期肝细胞癌 (HCC) 的生存结果. 增加IL-6表明接受息治疗的HCC患者的生存率更好.
科学领域:
- 在瘤学瘤学.
- 生物标志物 生物标志物
- 临床试验 临床试验
背景情况:
- 晚期肝细胞癌 (HCC) 的个性化管理需要准确预测治疗反应.
- 系统性炎症标志物正在研究它们在HCC的预后潜力.
研究的目的:
- 在先进的HCC患者中,评估基线和系统性白素6 (IL-6),白素8 (IL-8),血管内皮生长因子 (VEGF) 和脂多糖化物 (LPS) 系统水平的动态变化的预后值.
- 评估这些标志物与SORAMIC试验的息治疗臂的整体存活率 (OS) 的相关性.
主要方法:
- 从SORAMIC试验 (息手臂) 中对90名晚期HCC患者进行了探索性分析.
- 患者接受了90Y (90Y) 微球与sorafenib或单独sorafenib.
- 系统IL-6,IL-8,VEGF和LPS水平在基线和随访 (7-9周治疗后初始化) 测量.
主要成果:
- 增加IL-6度 (比基线低于16.8 pg/mL) 与改善的整体存活时间有显著关联 (中位数OS为16.3个月与8.9个月,p = 0.0354).
- 在基线,随访或这些时间点之间的变化时,没有发现VEGF或LPS与生存的显著相关性.
- 同样,IL-8水平与生存结果没有相关性.
结论:
- 治疗开始后7-9周测量血清IL-6水平的动态变化为接受息治疗的晚期HCC患者提供了宝贵的预后信息.
- 在这个患者队列中,IL-8,VEGF和LPS水平没有显示出类似的预后效用.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
684
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
684
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
309
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
309
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
1.1K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K